Pivotal trial to support marketing approval of regenerative cells processed with the Celution® System to commence in Q2 2022 SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that the FDA ...

The most successful drug or cell therapies are often mechanistically simple and work through a single molecule or cell type. But broadly speaking, when we consider more complex diseases—heart disease, ...

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc. announced today that it will present at Landmark’s Health Innovations Forum 2022. The invitation-only conference will take place virtually via Zoom on March ...

This graphic illustrates paracrine adhesion signaling on small extracellular vesicles, which secretes a protein called galectin-3, which promotes endocytosis so the vesicle can be absorbed into the ...